zymeworks Corporate Update and Third Quarter 2022 Financial Results Zymeworks Inc. NYSE: ZYME November 8, 2022 www.zymeworks.com 2 Forward-Looking Statements This presentation and the accompanying oral commentary include "forward-looking statements" or information within the meaning of applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation and the a ...

or Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41535 _____________________ ...

zymeworks Zymeworks Corporate Presentation September 2022 NYSE: ZYME www.zymeworks.com 2 Legal Disclaimer This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or per ...

Zanidatamab Clinical Development - Zanidatamab has Breakthrough Therapy designation by the FDA for previously-treated HER2 gene-amplified BTC[19] - HERIZON-GEA-01 study plans to enroll 714 patients across 30 countries[26] - In HER2+ First-Line GEA, Zanidatamab plus CAPOX showed a 93% confirmed objective response rate[32] - In HER2-Expressing Late-Line BTC, Zanidatamab monotherapy showed a 40% confirmed partial response rate and a 65% disease control rate[44] - In First-Line Breast Cancer, Zanidatamab in combination with Docetaxel showed a 90.5% confirmed objective response rate and a 95.2% disease control rate[49] ZW49 Clinical Development - Zanidatamab Zovodotin (ZW49) showed a 28% confirmed ORR and a 72% disease control rate in response-evaluable patients at 2.5 mg/kg Q3W[61] Partnerships and Financials - BeiGene has development and commercial rights to zanidatamab and ZW49 in Asia-Pacific (excluding Japan and India) with upfront payment of $40 million and up to $390 million in milestones[56] - BeiGene royalties are tiered up to 20% on sales in their territory[56] Strategic Priorities - Zymeworks aims to fully recruit HERIZON-BTC-01 and HERIZON-GEA-01 pivotal trials, targeting completion by YE 2023[69] - Zymeworks plans to advance two new product candidates to IND stage by YE 2024[69]

Zymeworks Inc. (NASDAQ:ZYME) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Jack Spinks - Associate Director of Investor Relations Ken Galbraith - Chair and CEO Dr. Neil Josephson - CMO Conference Call Participants Yigal Nochomovitz - Citi Nick Abbott - Wells Fargo Charles Zhu - Guggenheim Securities Stephen Willey - Stifel Amy Li - Jefferies Operator Thank you for standing. This is the conference operator. Welcome to Zymeworks Second Quarter 2022 Results Conference Call and ...

zymeworks Jefferies Healthcare Conference Ken Galbraith, Chair & CEO NYSE: ZYME June 8, 2022 www.zymeworks.com 2 Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, fu ...

Making Therapies that Make a Difference CORPORATE OVERVIEW NYSE: ZYME www.zymeworks.com Legal Disclaimer This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or perf ...

Financial Data and Key Metrics Changes - Zymeworks reported revenue of $1.9 million for Q1 2022, up from $0.6 million in Q1 2021, primarily from research support and partner payments [13] - Research and development expenses increased to $62.5 million in Q1 2022 from $44.3 million in Q1 2021, driven by higher clinical trial expenses for zanidatamab and restructuring costs [13][14] - General and administrative expenses rose to $12.1 million in Q1 2022 from $1.3 million in Q1 2021, including a non-cash stock-based compensation recovery of $5.1 million [15][16] - The net loss for Q1 2022 was $72.7 million, compared to $44.6 million in Q1 2021, attributed to increased operating expenses [17] - Cash resources were $300.5 million as of March 31, 2022, expected to fund operations into the second half of 2023 and beyond [19] Business Line Data and Key Metrics Changes - The increase in research and development expenses was primarily due to the initiation of the HERIZON-GEA-01 study and related drug manufacturing expenses [14] - The restructuring program led to severance and other expenses, impacting general and administrative costs [15][16] Market Data and Key Metrics Changes - The HERIZON-BTC-01 study completed enrollment ahead of schedule, with expectations to lock the study database by the end of 2022 and share results by early 2023 [22][24] - The FDA granted zanidatamab breakthrough therapy designation for patients with previously treated HER2-gene amplified biliary tract cancer, allowing for accelerated approval processes [24] Company Strategy and Development Direction - The company aims to build shareholder value by enabling patients to return home disease-free, focusing on developing therapies for hard-to-treat cancers [10] - Zymeworks is actively pursuing new partnerships and collaborations to extend its cash runway beyond 2023 [19][39] - The corporate goal includes advancing two new product candidates utilizing proprietary platform technologies and submitting two IND applications by the end of 2024 [37][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that increased operating expenses in Q1 2022 are expected to trend lower in upcoming quarters due to the completion of enrollment in clinical studies [18] - The company is focused on improving its balance sheet and has successfully closed a public offering despite challenging macroeconomic conditions [38] - Management emphasized the importance of integrating partnerships and collaborations throughout the product portfolio to enhance long-term value [51][76] Other Important Information - The company is in the process of selecting a new Chief Scientific Officer and has made significant progress in restructuring efforts [20][21] - Zymeworks is advancing its second clinical candidate, ZW49, and has completed enrollment in its expansion cohorts [32][33] Q&A Session Summary Question: Update on ASCO expectations and patient numbers - Management indicated that the patient numbers for ASCO presentations will be similar to previous Phase 2 data presentations, with interim data cuts expected [47] Question: Preference for early-stage platform deals versus specific asset transactions - Management is focused on integrating partnerships throughout the product portfolio to enhance development timing and broaden program scope [51] Question: Interpretation of ASCO's decision regarding CDK-46 combo presentation - Management noted that the decision was based on the maturity of the data, with plans to present a more mature version later [55] Question: Strategic updates on ZW49 and tumor types - Management is working on determining the next clinical study for ZW49 and will provide updates as soon as they have certainty [56] Question: Benchmarks for HERIZON-BTC in second-line disease - Management highlighted that there is significant unmet need in biliary tract cancer, and they expect better response rates than current chemotherapy options [63] Question: Proportion of patients enrolled in China and Korea for BTC - Management confirmed global enrollment for the study, with a focus on cooperation with BeiGene for regulatory discussions [80] Question: Data expectations from other zanidatamab indications - Management is enrolling in a Phase 2 study for front-line colorectal cancer but has not provided specific timelines for data presentation [90]

zymeworks Barclays Global Healthcare Conference Neil Klompas NYSE: ZYME Chief Operating Officer www.zymeworks.com 2 Legal Disclaimer This presentation includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future ev ...

zymeworks Corporate Update and Year-End 2021 Financial Results Zymeworks Inc NYSE: ZYME February 24, 2022www.zymeworks.com 2 Legal Disclaimer This presentation Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward looking statements. Forward-looking statements include statements that may relate to implementation of our strategic priorities; clinical development of our product candidates, related clinical trials, an ...